Company Filing History:
Years Active: 2024-2025
Title: Innovations of Eun-Ju Sohn in Vaccine Development
Introduction
Eun-Ju Sohn is a notable inventor based in Gyeongsangbuk-do, South Korea. She has made significant contributions to the field of vaccine development, particularly in relation to porcine diseases. With a total of two patents to her name, her work is recognized for its innovative approaches to combating viral infections in pigs.
Latest Patents
Eun-Ju Sohn's latest patents include a composition and preparation method for a porcine epidemic diarrhea (PED) virus vaccine. This invention relates to a PED virus protein that comprises an amino acid sequence represented by SEQ ID NO:5, along with a vaccine composition that utilizes this protein. Another significant patent involves a recombinant vector designed for expressing virus-like particles in plants. This technique allows for the preparation of a vaccine composition containing circovirus-like particles, utilizing a plant transformed with a chlorophyll-targeting recombinant vector. This innovative approach provides a method for isolating and purifying target proteins from transgenic plants, ultimately leading to the development of effective vaccine compositions.
Career Highlights
Eun-Ju Sohn is currently associated with Bioapplications Inc., where she continues to advance her research in vaccine technology. Her work has been instrumental in developing solutions for viral infections that affect livestock, thereby contributing to the agricultural sector's health and productivity.
Collaborations
Eun-Ju collaborates with Yongjik Lee, who is also involved in the research and development of innovative vaccine solutions. Their partnership enhances the potential for breakthroughs in the field of veterinary medicine.
Conclusion
Eun-Ju Sohn's contributions to vaccine development, particularly through her innovative patents, highlight her role as a leading inventor in the field. Her work not only addresses critical health issues in livestock but also paves the way for future advancements in vaccine technology.